Medpro Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 25 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.19 M
- Revenue Growth -33.15%
- Profit Growth -49.50%
- Ebitda 80.54%
- Net Worth 0.51%
- Total Assets 53.41%
About Medpro Pharma
Medpro Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 May 1999 and has a history of 25 years and eight months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.19 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Narayan Iyengar and Satish Narayan serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231TN1999PTC042551
-
Company No.
042551
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 May 1999
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Medpro Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayan Iyengar
|
Director | 26-May-1999 | Current |
|
Satish Narayan
|
Director | 26-May-1999 | Current |
Financial Performance of Medpro Pharma.
Medpro Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 33.15% decrease. The company also saw a substantial fall in profitability, with a 49.5% decrease in profit. The company's net worth moved up by a moderate rise of 0.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medpro Pharma?
In 2020, Medpro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Medpro Agencies Private LimitedNarayan Iyengar and Satish Narayan are mutual person
Charges (Loans)
₹0
₹0.19 M
Charges Breakdown by Lending Institutions
- The Karnataka Bank Ltd; : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Mar 2000 | The Karnataka Bank Ltd; | ₹0.19 M | Satisfied |
How Many Employees Work at Medpro Pharma?
Unlock and access historical data on people associated with Medpro Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medpro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medpro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
